It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The oral and gastrointestinal mucosae represent the main targets of the toxic effect of chemo and/or radiotherapy administered during the conditioning regimen before hematopoietic stem cell transplant (HSCT). These harmful consequences and the immunological complications that may occur after the transplant (such as Graft versus Host Disease, GvHD) are responsible for the clinical symptoms associated with mucositis during the aplasia phase, like pain, nausea, vomiting, and diarrhea. These toxicities could play a critical role in the oral and gastrointestinal microbiomes during the post-transplant phase, and the degree of microbial dysbiosis and dysregulation among different bacterial species could also be crucial in intestinal mucosa homeostasis, altering the host’s innate and adaptive immune responses and favoring abnormal immune responses responsible for the occurrence of GvHD. This prospective pediatric study aims to analyze longitudinally oral and gut microbiomes in 17 pediatric patients who received allogeneic HSCT for malignant and non-malignant diseases. The oral mucositis was mainly associated with an increased relative abundance of Fusobacteria, and Prevotella species, while Streptococcus descendants showed a negative correlation. The fecal microbiome of subjects affected by cutaneous acute GvHD (aGvHD) correlated with Proteobacteria. Oral mucosal microbiota undergoes changes after HSCT, Fusobacteria, and Prevotella represent bacterial species associated with mucositis and they could be the target for future therapeutic approaches, while fecal microbiome in patients with acute GvHD (aGvHD) revealed an increase of different class of Proteobacteria (Alphaproteobacteria and Deltaproteobacteria) and a negative correlation with the class of Gammaproteobacteria.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 IRCCS Istituto Giannina Gaslini, Hematopoietic Stem Cell Transplant Unit, Department of Hemato-Oncology, Genova, Italy (GRID:grid.419504.d) (ISNI:0000 0004 1760 0109)
2 IRCCS Istituto Giannina. Gaslini, Molecular Diagnostic Laboratory, Genova, Italy (GRID:grid.419504.d) (ISNI:0000 0004 1760 0109)
3 University of Genova, Department of Surgical and Diagnostic Sciences, Genova, Italy (GRID:grid.5606.5) (ISNI:0000 0001 2151 3065)
4 University of Milan, Department of Biomedical, Surgical and Dental Sciences, Milano, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822)
5 IRCCS Istituto G. Gaslini, Laboratory of Clinical Analysis, Genova, Italy (GRID:grid.419504.d) (ISNI:0000 0004 1760 0109)
6 IRCCS Ospedale Policlinico San Martino, Genova, Italy (GRID:grid.410345.7) (ISNI:0000 0004 1756 7871)